News Releases

Date Title
11/11/2016 Summary ToggleEnanta Announces New Data on FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2016
11/01/2016 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2016
10/26/2016 Summary ToggleEnanta Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference
10/03/2016 Summary ToggleEnanta Pharmaceuticals Announces New Data Presentations at The Liver Meeting® 2016
09/30/2016 Summary ToggleEnanta Pharmaceuticals Announces AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
09/29/2016 Summary ToggleEnanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
09/28/2016 Summary ToggleEnanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
09/23/2016 Summary ToggleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
08/29/2016 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
08/08/2016 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2016